Press releases
2024
Guard Therapeutics today announced that the first patient has been dosed in the phase 2b clinical study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE REGISTRATION OR OTHER MEASURES...
8 August, 2024
Guard Therapeutics receives regulatory EU approvals to include patients in its Phase 2b study POINTER
Guard Therapeutics announced today that, through the European application procedure, the company has received authorization from regulatory authorities and ethics committees in Spain, Germany, and the Czech Republic to include patients in the clinical Phase 2b study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in...
17 June, 2024
Guard Therapeutics carries out a directed share issue of approximately SEK 60 million and intends to carry out a repair issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE REGISTRATION OR OTHER MEASURES...
27 May, 2024
Guard Therapeutics research published in American Journal of Physiology – Renal Physiology
Guard Therapeutics today announced that the scientific journal American Journal of Physiology – Renal Physiology has published an article summarizing important preclinical results of the company's clinical drug candidate RMC-035. The results consistently demonstrate positive effects of RMC-035 in a large number of models for kidney injury...